Latest Period
Q2 2026
CUSIP: 738920107
Latest Period
Q2 2026
Institutions Reporting
1
Shares (Excl. Options)
33
Price
$5.33
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
Latest holder context comes from 1 institution filings for Q2 2026.
Security key
738920107
Latest holder period
Q2 2026
13F holders
1
13D/G owners
3
CIK / CUSIP context first
Broader feeds
Open recent reporting periods for CUSIP 738920107:
13D/G owners
Large-stake holder rows connected to Schedule 13D/G evidence.
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Friedman Lance | 4.5% | -42% | $1,037,706 | -$782,315 | 2,207,886 | -43% | Lance Friedman | 06 May 2025 |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 5.2% | $182,200 | 273,000 | Highbridge Capital Management, LLC | 31 Mar 2026 | |||
| Harraden Circle Investments, LLC | 0.31% | $70,500 | 150,000 | Harraden Circle Investments, LLC | 31 Mar 2025 |
As of 30 Jun 2026, 1 institutional investors reported holding 33 shares of Aspire Biopharma Holdings, Inc. - Common Stock, par value $0.0001 per share (ASBP). This represents 0% of the company’s total 5,250,000 outstanding shares.
Quarter history
Holder count, reported shares/value, and median price by quarter.
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 33 | $176 | -$12,580 | $5.33 | 1 |
| 2026 Q1 | 25,348 | $8,453 | -$841,693 | $0.67 | 2 |
| 2025 Q4 | 6,823,464 | $899,822 | +$486,842 | $0.13 | 30 |
| 2025 Q3 | 3,123,043 | $645,607 | +$222,104 | $0.21 | 25 |
| 2025 Q2 | 2,044,304 | $544,743 | -$131,309 | $0.27 | 16 |
| 2025 Q1 | 1,435,984 | $875,750 | +$875,750 | $0.58 | 15 |